An evaluation of dehydrated human amnion/chorion membrane allografts for pressure ulcer treatment: a case series

Abstract

Objective: Pressure ulcers (PU; also known as pressure injuries) affect about three million adults in the US and cost an estimated $11 billion dollars annually to treat. Prevention is most desirable, however, once a patient develops a PU, the focus shifts to effective treatment and rapid closure to improve health outcomes. We sought to evaluate outcomes in 10 patients with category II and III PUs treated with dehydrated human amnion/chorion membrane (dHACM) allografts. Method: All patients were treated with weekly application of dHACM plus standard wound care (SoC) and followed for eight weeks. Results: Of the PUs, two were category II and eight were category III. The average PU size at dHACM initiation was 3.42±1.76cm2. After the first application of dHACM 7/10 (70%) of PUs responded to treatment with a reduction in wound size. Within two weeks of dHACM initiation into the plan of care, 4/10 (40%) of PUs had reduced in size by >50%. By week four, 60% of PUs (6/10) had reduced in size by >50%. Overall, during the eight week evaluation period, 9/10 PUs reduced in size, three of which healed completely. Conclusion: dHACM allografts appear to be a viable treatment option for category II and III PUs.

Surgical Reconstruction of Stage 3 and 4 Pressure Injuries: A Literature Review and Proposed Algorithm from an Interprofessional Working Group

“…Such bioscaffolds commonly augment standard wound management of PIs (Table 1). [70][71][72][73][74][75][76][77][78][79][80][81][82][83][84] They are typically reapplied weekly to heal via secondary intention. When used with NPWT, the inclusion of a bioscaffold as part of standard wound management improves healing outcomes relative to NPWT alone in stage 4 PIs.…”

Chlorite-Oxidized Oxyamylose (COAM) Has Antibacterial Activity and Positively Affects Skin Wound Healing

“…The estimated prize of pressure sore treatment amounts to an annual recurrent cost of more than 10 billion dollars in the US alone. 4 …”

“…The estimated prize of pressure sore treatment amounts to an annual recurrent cost of more than 10 billion dollars in the US alone. 4 Aside pressure ulcers, common in immobilized elderly, diabetic foot ulcers, burns, traumata, impaired healing after radiotherapy, vascular insults (eg, venous thrombosis) and infections create necrotic wounds in urgent need of better treatments. As an alternative to the time-consuming and costly cell therapies, the application of various growth factors, including platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF) and other cytokines have been probed with limited success.…”